Last reviewed · How we verify

NCT03595280

Optimizing Risk Messages for Waterpipe Tobacco Cessation in Young Adults

Completed NA Results posted Last updated 20 October 2021
What this trial tests

NA trial testing Hookah tobacco risk messages in Hookah Smoking in 349 participants. Completed in 1 July 2021.

Timeline
28 August 2018
Primary endpoint
1 August 2020
1 July 2021

Quick facts

Lead sponsorGeorgetown University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment349
Start date28 August 2018
Primary completion1 August 2020
Estimated completion1 July 2021
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Georgetown University

Who can join

Adults 18 to 30, any sex, with Hookah Smoking. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Perceived Harm Primary · 6-months

Perceived harm of hookah tobacco is measured using valid self-report item assessing perceptions of how likely harms are to occur from hookah tobacco use (response range 1 no chance to 7 certain to happen). Greater perceived likelihood of harm is considered a better outcome. The assessment is administered immediately post intervention, 3-month follow-up, and 6-month follow-up, 6 month follow-up data reported.

GroupValue95% CI
Control4.13.9 – 4.4
Untailored Messages4.24.0 – 4.5
Tailored Messages4.54.2 – 4.8
Perceived Addictiveness Primary · 6-months

Perceived addictiveness of hookah tobacco is measured using valid self-report item assessing perceptions of how likely one is to become addicted to hookah tobacco (1 = no chance, 7 = certain to happen). Greater perceived likelihood of addictiveness is considered a better outcome. The assessment is administered immediately post-intervention, 3-month follow-up, and 6 month follow-up, 6-month follow-up data reported.

GroupValue95% CI
Control3.93.5 – 4.2
Untailored Messages3.93.6 – 4.3
Tailored Messages4.03.7 – 4.3
Worry About Harm Primary · 6-months

Worry about the harms of hookah tobacco is measured using a valid self-report item assessing how much participants worry about the risks of hookah tobacco (1 = Not at all, 7 = Very much). Greater worry about harm is considered a better outcome. The assessment is administered immediately post-intervention, 3-month follow-up, and 6 month follow-up, 6-month follow-up reported.

GroupValue95% CI
Control4.64.3 – 5.0
Untailored Messages4.13.8 – 4.5
Tailored Messages4.64.3 – 5.0
Worry About Addictiveness Primary · 6 months

Worry about the addictiveness of hookah tobacco is measured using a valid self-report item assessing how much participants worry about becoming addicted to hookah tobacco (1 = Not at all, 7 = very much). Greater perceived addictiveness is considered a better outcome. The assessment is administered immediately post-intervention, 3 month follow-up, and 6 month-follow-up, 6 month follow-up reported.

GroupValue95% CI
Control3.63.2 – 3.9
Untailored Messages3.73.3 – 4.1
Tailored Messages3.93.5 – 4.3
Motivation to Quit Primary · 6-months

Motivation to quit is measured using a valid self-report item assessing how much participants want to quit smoking hookah tobacco right now (1 = Not at all, 7 = Very). Greater motivation to quit is considered a better outcome. The assessment is administered immediately post-intervention, 3 month follow-up, and 6 month follow-up, 6-month follow-up reported.

GroupValue95% CI
Control4.03.5 – 4.4
Untailored Messages4.03.5 – 4.4
Tailored Messages3.53.0 – 4.1
Hookah Tobacco Use Frequency Primary · 6 months

Hookah tobacco use frequency is measured using a valid self-report item assessing how often participants have smoked hookah tobacco in the past 30 days. The item measures the number of days in the past month participants have smoked hookah tobacco. Less frequent hookah tobacco use is considered a better outcome. The assessment is administered immediately post-intervention, 3 month follow-up, and 6 month follow-up, 6-month follow-up reported.

GroupValue95% CI
Control4.33.0 – 5.6
Untailored Messages4.02.6 – 5.2
Tailored Messages3.52.0 – 5.0
Percent of Participants Who Quit Smoking Hookah Tobacco Primary · 6 months

Hookah tobacco cessation is measured using a single valid self-report item assessing if participants have stopped smoking hookah tobacco completely. The item asks if participants have completely stopped smoking hookah tobacco based on a yes/no response. Quitting hookah tobacco use (i.e., responses of "yes") is considered a better outcome. The assessment is administered immediately post intervention, 3 month follow-up, and 6 month follow-up, 6-month follow-up data reported.

GroupValue95% CI
Control29.20
Untailored Messages37.96
Tailored Messages48.98

Sponsor's own description

The objective of this study is to examine whether messages conveying the harms and addictiveness of waterpipe (i.e., hookah) tobacco delivered by mobile phone multimedia messaging (MMS) are effective for promoting hookah tobacco cessation among young adults ages 18 to 30 years.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Results of a Single Arm Pilot Study of a Mobile Messaging Intervention for Hookah Tobacco Cessation in Young Adults.
    Mays D, Phan L, Johnson AC, Tercyak KP, et al · · 2020 · cited 6× · PMID 32440243 · DOI 10.1177/1179173x20915200
  2. Correlates of motivation to quit waterpipe tobacco smoking among US young adults: implications for cessation interventions.
    Alalwan MA, Keller-Hamilton B, Long L, Lipkus I, et al · · 2023 · cited 4× · PMID 36880171 · DOI 10.1093/her/cyad010

Verify or expand the search:

Other recruiting trials for Hookah Smoking

Currently open trials in the same condition.

Other Georgetown University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03595280.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing